AIMS: To obtain pharmacokinetic data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following i.m. ARTS and rectal DHA administration. METHODS:Twelve Vietnamese patients with uncomplicated falciparum malaria were randomized to receive either i.v. or i.m. ARTS (120 mg), with the alternative preparation given 8 h later in an open crossover design. A further 12 patients were given i.v. ARTS (120 mg) at 0 h and rectal DHA (160 mg) 8 h later. RESULTS: Following i.v. bolus, ARTS had a peak concentration of 42 microm (16 mg l(-1), elimination t1/2 = 3.2 min, CL = 2.8 l h(-1) kg(-1) and V = 0.22 l kg(-1) . The Cmax for DHA was 9.7 microm (2.7 mg l(-1) ), t1/2 = 59 min, CL = 0.64 l h(-1) kg(-1) and V = 0.8 l kg(-1) . Following i.m. ARTS, Cmax was 2.3 microm (3.7 mg l(-1)), the apparent t1/2 = 41 min, CL = 2.9 l h(-1) kg(-1) and V = 2.6 l kg(-1). The relative bioavailability of DHA was 88%, Cmax was 4.1 microm (1.16 mg l(-1)) and t1/2 = 64 min. In the rectal DHA study, relative bioavailability of DHA was 16%. CONCLUSIONS: For patients with uncomplicated falciparum malaria i.m. ARTS is a suitable alternative to i.v. ARTS, at equal doses. To achieve plasma DHA concentrations equivalent to parenteral administration of ARTS, rectal DHA should be given at approximately four-fold higher milligram doses. Further studies are needed to determine whether these recommendations can be applied to patients with severe malaria.
RCT Entities:
AIMS: To obtain pharmacokinetic data for artesunate (ARTS) and its active metabolite dihydroartemisinin (DHA) following i.m. ARTS and rectal DHA administration. METHODS: Twelve Vietnamese patients with uncomplicated falciparum malaria were randomized to receive either i.v. or i.m. ARTS (120 mg), with the alternative preparation given 8 h later in an open crossover design. A further 12 patients were given i.v. ARTS (120 mg) at 0 h and rectal DHA (160 mg) 8 h later. RESULTS: Following i.v. bolus, ARTS had a peak concentration of 42 microm (16 mg l(-1), elimination t1/2 = 3.2 min, CL = 2.8 l h(-1) kg(-1) and V = 0.22 l kg(-1) . The Cmax for DHA was 9.7 microm (2.7 mg l(-1) ), t1/2 = 59 min, CL = 0.64 l h(-1) kg(-1) and V = 0.8 l kg(-1) . Following i.m. ARTS, Cmax was 2.3 microm (3.7 mg l(-1)), the apparent t1/2 = 41 min, CL = 2.9 l h(-1) kg(-1) and V = 2.6 l kg(-1). The relative bioavailability of DHA was 88%, Cmax was 4.1 microm (1.16 mg l(-1)) and t1/2 = 64 min. In the rectal DHA study, relative bioavailability of DHA was 16%. CONCLUSIONS: For patients with uncomplicated falciparum malaria i.m. ARTS is a suitable alternative to i.v. ARTS, at equal doses. To achieve plasma DHA concentrations equivalent to parenteral administration of ARTS, rectal DHA should be given at approximately four-fold higher milligram doses. Further studies are needed to determine whether these recommendations can be applied to patients with severe malaria.
Authors: V Ha; N H Nguyen; T B Tran; M C Bui; H P Nguyen; T H Tran; T Q Phan; K Arnold; T H Tran Journal: Trans R Soc Trop Med Hyg Date: 1997 Jul-Aug Impact factor: 2.184
Authors: X T Cao; D B Bethell; T P Pham; T T Ta; T N Tran; T T Nguyen; T T Pham; T T Nguyen; N P Day; N J White Journal: Trans R Soc Trop Med Hyg Date: 1997 May-Jun Impact factor: 2.184
Authors: A Sabchareon; P Attanath; P Chanthavanich; P Phanuaksook; V Prarinyanupharb; Y Poonpanich; D Mookmanee; P Teja-Isavadharm; D G Heppner; T G Brewer; T Chongsuphajaisiddhi Journal: Am J Trop Med Hyg Date: 1998-01 Impact factor: 2.345
Authors: P Newton; Y Suputtamongkol; P Teja-Isavadharm; S Pukrittayakamee; V Navaratnam; I Bates; N White Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191
Authors: R N Price; C Cassar; A Brockman; M Duraisingh; M van Vugt; N J White; F Nosten; S Krishna Journal: Antimicrob Agents Chemother Date: 1999-12 Impact factor: 5.191
Authors: T T Hien; T M E Davis; L V Chuong; K F Ilett; D X T Sinh; N H Phu; C Agus; G M Chiswell; N J White; J Farrar Journal: Antimicrob Agents Chemother Date: 2004-11 Impact factor: 5.191
Authors: Nguyen H Phu; Phung Q Tuan; Nicholas Day; Nguyen T H Mai; Tran T H Chau; Ly V Chuong; Dinh X Sinh; Nicholas J White; Jeremy Farrar; Tran T Hien Journal: Malar J Date: 2010-04-15 Impact factor: 2.979
Authors: Harin A Karunajeewa; Kenneth F Ilett; Kitiya Dufall; Adedayo Kemiki; Moses Bockarie; Michael P Alpers; P Hugh Barrett; Paolo Vicini; Timothy M E Davis Journal: Antimicrob Agents Chemother Date: 2004-08 Impact factor: 5.191
Authors: Patrick S Twomey; Bryan L Smith; Cathy McDermott; Anne Novitt-Moreno; William McCarthy; S Patrick Kachur; Paul M Arguin Journal: Ann Intern Med Date: 2015-10-06 Impact factor: 25.391
Authors: I C E Hendriksen; G Mtove; A Kent; S Gesase; H Reyburn; M M Lemnge; N Lindegardh; N P J Day; L von Seidlein; N J White; A M Dondorp; J Tarning Journal: Clin Pharmacol Ther Date: 2013-02-08 Impact factor: 6.875